Bart Leroy (Ghent University Hospital, Belgium) gave us an update on the latest developments on retinal gene therapy from EURETINA 2019, and shared some patient experiences with the treatment so far.
Questions:
1. What are the main challenges of diagnosing and treating patients with inherited retinal diseases? 0:03
2. Can you give us an overview of the key sessions around retinal gene therapy at EURETINA 2019? 1:37
3. How have retinal gene therapies been received by patients? 5:57
Support: No funding was received in the production of this video.
Disclosures: Bart Leroy reports work with Novartis, Bayer, Second Sight and other companies that finance research in his hospital but has no personal financial interest.
